IFNA1 and COVID-19: With IFN-AABs present in up to 18% of deceased COVID-19 patients [19] and given the limited therapeutic options for severely affected COVID-19 patients, testing specific therapeutic approaches is of high urgency, yet clinically implementable strategies for rapid and early identification of IFN-AAB-positive patients upfront are missing.